Who Buys Pembrolizumab from India — 66 Importers Behind a $1.9M Market

The importation of Pembrolizumab from India involves various buyer segments, each with distinct purchasing behaviors:

• Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives ($0.13M) fall into this category. These institutions procure Pembrolizumab directly to administer to patients within their facilities, often placing large, periodic orders to meet patient demand.

• Individual Buyers: Names such as Karlene Small ($0.05M) and Keisha Young-Henry ($0.05M) from Jamaica suggest individual purchasers, possibly patients or their representatives, importing the drug for personal use. Their buying patterns are typically characterized by smaller, irregular orders based on personal treatment schedules.

• Distributors: Entities like MERMISI LLC in Georgia ($0.06M) likely serve as intermediaries, purchasing Pembrolizumab in bulk to supply to healthcare providers or pharmacies. Distributors usually place consistent, sizable orders to maintain inventory levels and meet market demand.

• Re-exporters: Buyers listed as "AS PER INVOICE" ($0.11M) and "F AGAINST PROFORMA INVOICE" ($0.05M) in Brazil may represent re-exporters. These entities import Pembrolizumab with the intent to export it to other markets, often capitalizing on price differentials or regulatory environments. Their purchasing behavior can be opportunistic, influenced by market conditions and demand in target export destinations.

Understanding these segments is crucial for tailoring marketing strategies, forecasting demand, and ensuring compliance with regulatory requirements in diverse markets.

Importing Pembrolizumab into the top five importing countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: ANVISA requires a comprehensive dossier, including clinical data and manufacturing details, for drug registration.
• Estimated Timeline: The process can take approximately 12 to 24 months, depending on the completeness of the application and ANVISA's workload.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30021500 are subject to a standard import duty of 8%, with additional taxes such as the Industrialized Product Tax (IPI) and the Merchandise and Service Circulation Tax (ICMS) varying by state.

• Zimbabwe:
• Regulatory Authority: Medicines Control Authority of Zimbabwe (MCAZ).
• Import Registration Process: MCAZ mandates submission of an application with supporting documents, including quality, safety, and efficacy data.
• Estimated Timeline: The registration process typically spans 6 to 12 months.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties to promote access to essential medicines.

• Maldives:
• Regulatory Authority: Maldives Food and Drug Authority (MFDA).
• Import Registration Process: Importers must obtain an import license from the MFDA, providing product details and manufacturer information.
• Estimated Timeline: The approval process usually takes 1 to 3 months.
• Import Tariff/Duty: Pharmaceuticals are typically exempt from import duties to ensure affordable healthcare.

• Jamaica:
• Regulatory Authority: Pharmacy Council of Jamaica.
• Import Registration Process: Importers must register the drug with the Pharmacy Council, submitting necessary documentation for evaluation.
• Estimated Timeline: The registration process can take 6 to 9 months.
• Import Tariff/Duty: Pharmaceuticals are generally subject to a 5% import duty, with possible exemptions for essential medicines.

• Georgia:
• Regulatory Authority: State Regulation Agency for Medical Activities.
• Import Registration Process: Requires submission of an application with comprehensive product information and compliance with local standards.
• Estimated Timeline: The process typically takes 6 to 12 months.
• Import Tariff/Duty: Pharmaceuticals are usually exempt from import duties to facilitate access to healthcare products.

Navigating these regulatory landscapes is essential for successful market entry and sustained distribution of Pembrolizumab in these countries.

The demand for Pembrolizumab across importing countries is influenced by several factors:

• Disease Prevalence: Rising incidences of cancers, particularly those treatable with Pembrolizumab, such as non-small cell lung cancer and melanoma, drive demand. For instance, Brazil has seen an increase in cancer cases, necessitating advanced therapeutic options.

• Government Healthcare Programs: Initiatives aimed at improving cancer care, including funding for advanced treatments, bolster demand. Countries like Brazil and Jamaica have national cancer control programs that facilitate access to immunotherapies.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage lead to increased access to essential medicines. The Maldives, for example, has expanded healthcare services, ensuring broader access to treatments like Pembrolizumab.

• WHO Essential Medicines List Procurement: Inclusion of cancer therapies in national essential medicines lists, guided by WHO recommendations, prompts procurement by public health systems.

• Tender-Based Purchasing: Government tenders for pharmaceuticals create opportunities for suppliers. Zimbabwe and Georgia often utilize tender systems to procure medicines, including oncology drugs.

With 66 buyers across 21 countries, the market for Pembrolizumab imported from India reflects a growing global need for effective cancer treatments, presenting significant opportunities for suppliers attuned to these demand drivers.

The importation of Pembrolizumab from India involves various buyer segments, each with distinct purchasing behaviors:

• Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives ($0.13M) fall into this category. These institutions procure Pembrolizumab directly to administer to patients within their facilities, often placing large, periodic orders to meet patient demand.

• Individual Buyers: Names such as Karlene Small ($0.05M) and Keisha Young-Henry ($0.05M) from Jamaica suggest individual purchasers, possibly patients or their representatives, importing the drug for personal use. Their buying patterns are typically characterized by smaller, irregular orders based on personal treatment schedules.

• Distributors: Entities like MERMISI LLC in Georgia ($0.06M) likely serve as intermediaries, purchasing Pembrolizumab in bulk to supply to healthcare providers or pharmacies. Distributors usually place consistent, sizable orders to maintain inventory levels and meet market demand.

• Re-exporters: Buyers listed as "AS PER INVOICE" ($0.11M) and "F AGAINST PROFORMA INVOICE" ($0.05M) in Brazil may represent re-exporters. These entities import Pembrolizumab with the intent to export it to other markets, often capitalizing on price differentials or regulatory environments. Their purchasing behavior can be opportunistic, influenced by market conditions and demand in target export destinations.

Understanding these segments is crucial for tailoring marketing strategies, forecasting demand, and ensuring compliance with regulatory requirements in diverse markets.

Importing Pembrolizumab into the top five importing countries involves navigating specific regulatory frameworks:

• Brazil:
• Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
• Import Registration Process: ANVISA requires a comprehensive dossier, including clinical data and manufacturing details, for drug registration.
• Estimated Timeline: The process can take approximately 12 to 24 months, depending on the completeness of the application and ANVISA's workload.
• Import Tariff/Duty: Pharmaceutical products under HS Code 30021500 are subject to a standard import duty of 8%, with additional taxes such as the Industrialized Product Tax (IPI) and the Merchandise and Service Circulation Tax (ICMS) varying by state.

• Zimbabwe:
• Regulatory Authority: Medicines Control Authority of Zimbabwe (MCAZ).
• Import Registration Process: MCAZ mandates submission of an application with supporting documents, including quality, safety, and efficacy data.
• Estimated Timeline: The registration process typically spans 6 to 12 months.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties to promote access to essential medicines.

• Maldives:
• Regulatory Authority: Maldives Food and Drug Authority (MFDA).
• Import Registration Process: Importers must obtain an import license from the MFDA, providing product details and manufacturer information.
• Estimated Timeline: The approval process usually takes 1 to 3 months.
• Import Tariff/Duty: Pharmaceuticals are typically exempt from import duties to ensure affordable healthcare.

• Jamaica:
• Regulatory Authority: Pharmacy Council of Jamaica.
• Import Registration Process: Importers must register the drug with the Pharmacy Council, submitting necessary documentation for evaluation.
• Estimated Timeline: The registration process can take 6 to 9 months.
• Import Tariff/Duty: Pharmaceuticals are generally subject to a 5% import duty, with possible exemptions for essential medicines.

• Georgia:
• Regulatory Authority: State Regulation Agency for Medical Activities.
• Import Registration Process: Requires submission of an application with comprehensive product information and compliance with local standards.
• Estimated Timeline: The process typically takes 6 to 12 months.
• Import Tariff/Duty: Pharmaceuticals are usually exempt from import duties to facilitate access to healthcare products.

Navigating these regulatory landscapes is essential for successful market entry and sustained distribution of Pembrolizumab in these countries.

The demand for Pembrolizumab across importing countries is influenced by several factors:

• Disease Prevalence: Rising incidences of cancers, particularly those treatable with Pembrolizumab, such as non-small cell lung cancer and melanoma, drive demand. For instance, Brazil has seen an increase in cancer cases, necessitating advanced therapeutic options.

• Government Healthcare Programs: Initiatives aimed at improving cancer care, including funding for advanced treatments, bolster demand. Countries like Brazil and Jamaica have national cancer control programs that facilitate access to immunotherapies.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage lead to increased access to essential medicines. The Maldives, for example, has expanded healthcare services, ensuring broader access to treatments like Pembrolizumab.

• WHO Essential Medicines List Procurement: Inclusion of cancer therapies in national essential medicines lists, guided by WHO recommendations, prompts procurement by public health systems.

• Tender-Based Purchasing: Government tenders for pharmaceuticals create opportunities for suppliers. Zimbabwe and Georgia often utilize tender systems to procure medicines, including oncology drugs.

With 66 buyers across 21 countries, the market for Pembrolizumab imported from India reflects a growing global need for effective cancer treatments, presenting significant opportunities for suppliers attuned to these demand drivers.